Vitor Bonetti Valente
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Vitor Bonetti Valente has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Galera Bernabé
Psychosomatic Research Center, Oral Oncology Center, São Paulo State University (UNESP), School of Dentistry, Araçatuba, São Paulo, Brazil
6 shared publications - Glauco Issamu Miyahara
Psychosomatic Research Center, Oral Oncology Center, São Paulo State University (UNESP), School of Dentistry, Araçatuba, São Paulo, Brazil
5 shared publications Giseli Mitsuy Kayahara
Department of Diagnosis and Surgery School of Dentistry, São Paulo State University (Unesp) Araçatuba, São Paulo Brazil
4 shared publications- Felipe Paiva Fonseca
Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
3 shared publications - Ana Lívia Santos‐Sousa
Psychosomatic and Education Research Center Oral Oncology Center São Paulo State University (Unesp) School of Dentistry Araçatuba São Paulo Brazil
2 shared publications Diovana de Melo Cardoso
2 shared publications
Latest Publications
- Open Access
- 19 February 2026
- Published by Wiley in Psycho-Oncology
- Vol. 35 (2) , e70404
Specific Depressive Symptoms and Primary Tumor Location as Potential Predictors of Smoking Maintenance After Head and Neck Cancer Treatment
Background: Despite the known benefits of smoking cessation for head and neck cancer (HNC) patients, a significant proportion continue to use tobacco after treatment. Although the causes of this phenomenon are multifactorial, the underlying psychological mechanisms are still poorly understood. Aim: Investigate the influence of sociodemographic, clinicopathological, and psychological factors on smoking cessation after treatment of HNC. Methods: This study included 71 smoking HNC patients who had completed cancer treatment for at least 12 months. Clinicopathological characteristics and anxiety and depression symptoms extracted the Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI) were evaluated in the pre‐treatment period. Data on smoking history was assessed through a semi‐structured interview. Results: A proportion of patients with HNC patients (39.4%) continued to smoke immediately after completing cancer treatment, with this proportion rising to 43.7% after 12 months of treatment. Logistic regression analyses showed that the occurrence of the primary tumor in the oral cavity ( β = 6.891, P = 0.008) and the psychological symptom of sadness measured by the BDI ( β = 5.279, P = 0.023) were predictive of smoking maintenance 12 months after the end of cancer treatment. Feeling like a failure before cancer treatment was the only predictor variable for smoking maintenance immediately after and 12 months after the end of treatment ( β = 13.455, p < 0.001; β = 4.537, P = 0.043; respectively). Conclusion: This study presents exploratory insights that identifies pre‐treatment specific depressive symptoms and primary tumor location as promising predictive factors for continued tobacco use in patients treated for head and neck cancer.
- 19 February 2026
- Published by Wiley in Psycho-Oncology
- Vol. 35 (2) , e70404
Open AccessSpecific Depressive Symptoms and Primary Tumor Location as Potential Predictors of Smoking Maintenance After Head and Neck Cancer Treatment
Background: Despite the known benefits of smoking cessation for head and neck cancer (HNC) patients, a significant proportion continue to use tobacco after treatment. Although the causes of this phenomenon are multifactorial, the underlying psychological mechanisms are still poorly understood. Aim: Investigate the influence of sociodemographic, clinicopathological, and psychological factors on smoking cessation after treatment of HNC. Methods: This study included 71 smoking HNC patients who had completed cancer treatment for at least 12 months. Clinicopathological characteristics and anxiety and depression symptoms extracted the Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI) were evaluated in the pre‐treatment period. Data on smoking history was assessed through a semi‐structured interview. Results: A proportion of patients with HNC patients (39.4%) continued to smoke immediately after completing cancer treatment, with this proportion rising to 43.7% after 12 months of treatment. Logistic regression analyses showed that the occurrence of the primary tumor in the oral cavity ( β = 6.891, P = 0.008) and the psychological symptom of sadness measured by the BDI ( β = 5.279, P = 0.023) were predictive of smoking maintenance 12 months after the end of cancer treatment. Feeling like a failure before cancer treatment was the only predictor variable for smoking maintenance immediately after and 12 months after the end of treatment ( β = 13.455, p < 0.001; β = 4.537, P = 0.043; respectively). Conclusion: This study presents exploratory insights that identifies pre‐treatment specific depressive symptoms and primary tumor location as promising predictive factors for continued tobacco use in patients treated for head and neck cancer.
- Open Access
- 29 August 2025
- Published by Wiley in Journal of Dental Education
- Vol. 90 (4) , 500-507
Difficulties and Feelings Experienced by Undergraduate Dental Students When Caring for Patients
Purpose: Dealing with the patient's illness process is part of the academic trajectory of healthcare students. The relationship between patients and their healthcare professionals can be complex and challenging, especially for undergraduate dental students. The purpose of this study was to evaluate the perceptions, feelings, and difficulties of dental students triggered when caring for patients during their undergraduate course. Methods: Eighty‐six undergraduate dental students responded to a semi‐structured questionnaire about their experiences with patient care in the oral medicine clinic. Results: Forty‐two students (48.8%) felt uncomfortable with the patients’ anamnesis questions. Among these, the inquiries about sexually transmitted infections (STIs) were the most discomforting topic to address with the patient (65%), followed by drug abuse (35%) and sexual behavior (15%). According to the students, the most difficult topic to discuss with the patient was a negative diagnosis (40%), followed by STIs and sexual behavior (25.3%), and physical and sexual violence (20%). During patient care, the main challenging issue was dealing with uncooperative patients, reported by 29 students (36.7%). About the challenges faced during patient interviews, the majority of the students reported feeling bad when the patient shared a negative life story (90.7%) or when they described a traumatic life event (83.7%). A portion of the students (26.7%) reported that this discomfort in hearing a patient's negative life story can negatively impact the care they provide to the patient. Conclusion: Dental students experience evident difficulties in clinical practice with patients in the oral medicine clinic, especially in relation to some themes addressed during the anamnesis. Knowledge of these difficulties is essential to develop new learning and teaching strategies and improve the students’ professional training during their dental undergraduate course.
- 29 August 2025
- Published by Wiley in Journal of Dental Education
- Vol. 90 (4) , 500-507
Open AccessDifficulties and Feelings Experienced by Undergraduate Dental Students When Caring for Patients
Purpose: Dealing with the patient's illness process is part of the academic trajectory of healthcare students. The relationship between patients and their healthcare professionals can be complex and challenging, especially for undergraduate dental students. The purpose of this study was to evaluate the perceptions, feelings, and difficulties of dental students triggered when caring for patients during their undergraduate course. Methods: Eighty‐six undergraduate dental students responded to a semi‐structured questionnaire about their experiences with patient care in the oral medicine clinic. Results: Forty‐two students (48.8%) felt uncomfortable with the patients’ anamnesis questions. Among these, the inquiries about sexually transmitted infections (STIs) were the most discomforting topic to address with the patient (65%), followed by drug abuse (35%) and sexual behavior (15%). According to the students, the most difficult topic to discuss with the patient was a negative diagnosis (40%), followed by STIs and sexual behavior (25.3%), and physical and sexual violence (20%). During patient care, the main challenging issue was dealing with uncooperative patients, reported by 29 students (36.7%). About the challenges faced during patient interviews, the majority of the students reported feeling bad when the patient shared a negative life story (90.7%) or when they described a traumatic life event (83.7%). A portion of the students (26.7%) reported that this discomfort in hearing a patient's negative life story can negatively impact the care they provide to the patient. Conclusion: Dental students experience evident difficulties in clinical practice with patients in the oral medicine clinic, especially in relation to some themes addressed during the anamnesis. Knowledge of these difficulties is essential to develop new learning and teaching strategies and improve the students’ professional training during their dental undergraduate course.
- 17 July 2025
- Published by Wiley in The Laryngoscope
- Vol. 136 (1) , 236-239
Talquetamab‐Induced Dysgeusia Successfully Treated With Photobiomodulation Therapy
Multiple myeloma is a malignancy characterized by clonal proliferation of plasma cells in the bone marrow. The treatment of patients with relapsed or refractory multiple myeloma remains a challenge. Talquetamab is a recently approved drug, a first‐in‐class GPRC5D‐targeting T‐cell redirecting bispecific antibody, for treatment of patients with triple‐class exposed relapsed/refractory multiple myeloma. Patients who underwent drug therapy have experienced oral side effects such as xerostomia and dysgeusia. This report describes the case of a 61‐year old man with triple‐class exposed refractory multiple myeloma who developed talquetamab‐related dysgeusia that was successfully treated with photobiomodulation (PBM). The patient began to complain of loss of taste three days after the administration of talquetamab. PBM was performed every 48 h with 25 J/cm 2 per treatment field using the Therapy EC device (DMC; model number: #75153; red: 660 nm ±10 nm; infrared: 808 nm ±10 nm; fixed power of 100 mW ±20%; beam area of 0.04 cm 2 , and irradiance of 2.5 W/cm 2 ) during the talquetamab escalation phase. The application of laser was performed in 78 points distributed throughout the oral cavity. After 7 days/third session of PBM, the patient displayed a significant improvement in sensitivity to tastes, mainly salty and bitter. After 7 weeks of follow‐up, there was a slight reduction in sensibility to salty and no change in other tastes. The current clinical report demonstrated the potential effectiveness of a PBM protocol developed for the treatment of talquetamab‐related dysgeusia. The management of this oral side effect using PBM could prevent treatment interruption and improve the patients' quality of life.
- 17 July 2025
- Published by Wiley in The Laryngoscope
- Vol. 136 (1) , 236-239
Talquetamab‐Induced Dysgeusia Successfully Treated With Photobiomodulation Therapy
Multiple myeloma is a malignancy characterized by clonal proliferation of plasma cells in the bone marrow. The treatment of patients with relapsed or refractory multiple myeloma remains a challenge. Talquetamab is a recently approved drug, a first‐in‐class GPRC5D‐targeting T‐cell redirecting bispecific antibody, for treatment of patients with triple‐class exposed relapsed/refractory multiple myeloma. Patients who underwent drug therapy have experienced oral side effects such as xerostomia and dysgeusia. This report describes the case of a 61‐year old man with triple‐class exposed refractory multiple myeloma who developed talquetamab‐related dysgeusia that was successfully treated with photobiomodulation (PBM). The patient began to complain of loss of taste three days after the administration of talquetamab. PBM was performed every 48 h with 25 J/cm 2 per treatment field using the Therapy EC device (DMC; model number: #75153; red: 660 nm ±10 nm; infrared: 808 nm ±10 nm; fixed power of 100 mW ±20%; beam area of 0.04 cm 2 , and irradiance of 2.5 W/cm 2 ) during the talquetamab escalation phase. The application of laser was performed in 78 points distributed throughout the oral cavity. After 7 days/third session of PBM, the patient displayed a significant improvement in sensitivity to tastes, mainly salty and bitter. After 7 weeks of follow‐up, there was a slight reduction in sensibility to salty and no change in other tastes. The current clinical report demonstrated the potential effectiveness of a PBM protocol developed for the treatment of talquetamab‐related dysgeusia. The management of this oral side effect using PBM could prevent treatment interruption and improve the patients' quality of life.
- 30 March 2025
- Published by Wiley in Head & Neck
- Vol. 47 (8) , 2290-2312
Associations of Pain, Anxiety, and Depressive Symptoms With Sleep Outcomes in Patients With Head and Neck Squamous Cell Carcinoma: A Cross‐Sectional Observational Study
Background: This exploratory cross‐sectional observational study sought to characterize sleep quality and evaluate its association with sociodemographic, clinicopathological, behavioral, and psychological variables in patients with head and neck squamous cell carcinoma (HNSCC).Patients and Methods: Sleep problems from 132 HNC patients were assessed before starting oncological treatment through the questionnaires Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS), and STOP‐Bang. Anxiety and depression symptoms were evaluated using the Hospital Anxiety and Depression Scale. Univariate analysis and multivariate logistic regression were performed to evaluate factors associated with sleep problems in HNSCC patients.Results: About 50% of the HNSCC patients reported poor overall sleep quality on the PSQI. Insomnia, excessive daytime sleepiness, and high risk of apnea were observed in 19%, 15%, and 54% of HNSCC patients, respectively. Our results showed that pain was associated with overall poor PSQI sleep quality and lower PSQI sleep efficiency, while the presence of regional metastasis was linked to overall PSQI good sleep. No other clinicopathological or behavioral (i.e., alcohol and tobacco use) variables were related to sleep outcomes. Higher occurrence of anxiety symptoms was related to poor overall PSQI sleep quality, decreased PSQI sleep efficiency, PSQI daytime dysfunction, and ISI insomnia. Moreover, higher occurrence of depression symptoms was associated with lower PSQI sleep latency and PSQI duration, and the occurrence of ESS excessive daytime sleepiness.Conclusion: Pain, anxiety, and depressive symptoms were associated with poor sleep quality and sleep problems in HNSCC patients before starting treatment. No sociodemographic or behavioral (i.e., alcohol and tobacco use) variables were related to sleep outcomes. Likewise, tumor location, T classification, and clinical staging were not linked to sleep quality and disorders in HNSCC patients.
- 30 March 2025
- Published by Wiley in Head & Neck
- Vol. 47 (8) , 2290-2312
Associations of Pain, Anxiety, and Depressive Symptoms With Sleep Outcomes in Patients With Head and Neck Squamous Cell Carcinoma: A Cross‐Sectional Observational Study
Background: This exploratory cross‐sectional observational study sought to characterize sleep quality and evaluate its association with sociodemographic, clinicopathological, behavioral, and psychological variables in patients with head and neck squamous cell carcinoma (HNSCC).Patients and Methods: Sleep problems from 132 HNC patients were assessed before starting oncological treatment through the questionnaires Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS), and STOP‐Bang. Anxiety and depression symptoms were evaluated using the Hospital Anxiety and Depression Scale. Univariate analysis and multivariate logistic regression were performed to evaluate factors associated with sleep problems in HNSCC patients.Results: About 50% of the HNSCC patients reported poor overall sleep quality on the PSQI. Insomnia, excessive daytime sleepiness, and high risk of apnea were observed in 19%, 15%, and 54% of HNSCC patients, respectively. Our results showed that pain was associated with overall poor PSQI sleep quality and lower PSQI sleep efficiency, while the presence of regional metastasis was linked to overall PSQI good sleep. No other clinicopathological or behavioral (i.e., alcohol and tobacco use) variables were related to sleep outcomes. Higher occurrence of anxiety symptoms was related to poor overall PSQI sleep quality, decreased PSQI sleep efficiency, PSQI daytime dysfunction, and ISI insomnia. Moreover, higher occurrence of depression symptoms was associated with lower PSQI sleep latency and PSQI duration, and the occurrence of ESS excessive daytime sleepiness.Conclusion: Pain, anxiety, and depressive symptoms were associated with poor sleep quality and sleep problems in HNSCC patients before starting treatment. No sociodemographic or behavioral (i.e., alcohol and tobacco use) variables were related to sleep outcomes. Likewise, tumor location, T classification, and clinical staging were not linked to sleep quality and disorders in HNSCC patients.
- 1 January 2025
- Published by Springer Nature
- p. 343-354
Diffuse Large B-Cell Lymphoma (Not Otherwise Specified)
- 1 January 2025
- Published by Springer Nature
- p. 343-354
Diffuse Large B-Cell Lymphoma (Not Otherwise Specified)
- 9 August 2024
- Published by Elsevier in The Journal of the American Dental Association
- Vol. 155 (9) , 781-786
A rare development of classical Hodgkin lymphoma in the head and neck region
- 9 August 2024
- Published by Elsevier in The Journal of the American Dental Association
- Vol. 155 (9) , 781-786
A rare development of classical Hodgkin lymphoma in the head and neck region
- 21 January 2024
- Published by Elsevier in The Journal of the American Dental Association
- Vol. 155 (4) , 344-348
Primary manifestation of HIV-related Burkitt lymphoma in the oral and maxillofacial regions
- 21 January 2024
- Published by Elsevier in The Journal of the American Dental Association
- Vol. 155 (4) , 344-348
Primary manifestation of HIV-related Burkitt lymphoma in the oral and maxillofacial regions
- 7 September 2023
- Published by Wiley in Oral Diseases
- Vol. 30 (4) , 1743-1745
Ulcerated lesion in the hard palate of a child
- 7 September 2023
- Published by Wiley in Oral Diseases
- Vol. 30 (4) , 1743-1745
Ulcerated lesion in the hard palate of a child